Analysis of syndecan-4 core protein as a receptor for antithrombin III

• Project/Area Number: 18390479
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Emergency medicine
• Research Institution: Akita University
• Principal Investigator: MINAMIYA Yoshihiro Akita University, School of Medicine, Associate Professor (30239321)
• Co-Investigator(Kenkyū-buntansha): OGAWA Jun-ichi Akita University, School of Medicine, Professor (20112774) ; SAITO Hajime Akita University, School of Medicine, Lecturer (20323149) ; KATAYOSE Yoshihisa Akita University, School of Medicine, Lecturer (40282165)
• Project Period (FY): 2006 – 2007
• Project Status: Completed (Fiscal Year 2007)
• Budget Amount: ¥17,490,000 (Direct Cost: ¥15,300,000、Indirect Cost: ¥2,190,000); Fiscal Year 2007: ¥9,490,000 (Direct Cost: ¥7,300,000、Indirect Cost: ¥2,190,000); Fiscal Year 2006: ¥8,000,000 (Direct Cost: ¥8,000,000)
• Keywords: Acute Respirator Distress Syndrome / antithrombin III / syndecan-4

Research Abstract

Recently, the outcome of the treatment for Acute Respiratory Distress Syndrome (ARDS) has been improved. However, the prognosis of ARDS is still poor. Especially, the prognosis of ARDS associated with sepsis is extremely poor. Therefore, we should establish the method to cure ARDS as soon as possible. Antithrombin III (AT) sometimes applies for the treatment of disseminated intravascular coagulation, because of its anti-coagulant effect. AT binds and inactivates thrombin and other coagulants. On the other hand, the meta-analysis demonstrated that the effectiveness of AT for severe sepsis. This results suggests that AT has an anti-inflammatory effect. We demonstrated that AT most likely reduces F-actin formation in neutrophil thereby reducing neutrophil accumulation in the lung, which would in turn inhibit oxygen radical production in the rat lung. We also demonstrated that pretreatment of neutrophil with both AT and latent-AT attenuate F-actin formation and decreasing of deformability due to fMLP treatment. These data suggest that there must be new receptor for AT on the cell membrane of neutrophil. In 2006, at first we examined expression of syndecan-4 and removed heparan sulfate from isolated human neutrophil. However, for these kinds of experiment, we need a large amount of neutrophil. In 2007, we found that human tumor cell line HTI080 express syndecan-4. Therefore, we used HT1080 instead of isolated human neutrophil. After removing heparan sulfate from cell surface of the cultured tumor cell line HT1080 using heparinase or sodium chlorate, AT was still bound to AT except for heparin binding site. Then, we isolated and analyzed the proteins bound to AT using mass spectrometry. Syndecan-4, one of the glycosaminoglycan, was detected even when heparin sulfate was removed from the cell surface using heparinase or sodium chlorate. To further proof the results, we applied IP-western and demonstrated that AT bound to syndecan-4 even after removing heparin sulfate using heparinase or sodium chlorate. These data suggest syndecan-4 is a receptor for AT.